
Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Your AI-Trained Oncology Knowledge Connection!


Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Eytan M. Stein, MD, discusses how the FDA approval of revumenib could improve survival outcomes in KMT2A-rearranged relapsed/refractory acute leukemia.

Eytan M. Stein, MD, discusses the ongoing development and investigation of therapies targeting splicing mutations in hematologic malignancies.

Eytan M. Stein, MD, discusses the phase 2 SELECT-AML-1 trial in patients with newly diagnosed acute myeloid leukemia.

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.

Published: December 6th 2024 | Updated:

Published: December 12th 2024 | Updated:

Published: June 10th 2022 | Updated:

Published: December 7th 2023 | Updated:

Published: December 7th 2014 | Updated: